Hyaluronic acid: Function and location in the urothelial barrier for bladder pain syndrome/interstitial cystitis, an in vitro study.
Disruption of the glycosaminoglycan (GAG)-layer and urothelial barrier is an important aspect of the pathophysiology of bladder pain syndrome/ interstitial cystitis. Intravesical hyaluronic acid (HA) is often used in treatments for IC/BPS, however the role in the urothelial barrier is unknown. This...
Saved in:
| Main Authors: | Charlotte J van Ginkel, Cléo D M Baars, Dorien M Tiemessen, Cornelius F J Jansen, Frank M J Martens, Jack A Schalken, Dick A W Janssen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0318277 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Carry-over effects in GAG therapy efficacy trial solution for bladder pain syndrome/interstitial cystitis (GETSBI study): an interim analysis
by: Thomas J Hoogeboom, et al.
Published: (2025-06-01) -
Microbiome profiling in patients with Bladder Pain Syndrome/Interstitial cystitis
by: Puck Oude Elferink, et al.
Published: (2025-06-01) -
Pilot Study of Cystochon® (Cranberry Extract, Chondroitin Sulfate, and Hyaluronic Acid Complex) in Interstitial Cystitis/Bladder Pain Syndrome
by: Kwang Taek Kim, et al.
Published: (2022-08-01) -
Re: Hydrodistention of the Bladder for the Treatment of Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)
by: İlker Şen
Published: (2017-06-01) -
BOTULINUM TOXIN A FOR THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
by: V. L. Medvedev, et al.
Published: (2017-10-01)